上海2025年3月26日 /美通社/ -- 迈威生物 (688062.SH)，一家全产业链布局的创新型生物制药公司，宣布将于当地时间2025年4月25-30日在美国芝加哥举行的2025年美国癌症研究协会 (AACR) 年会，以壁报形式公布6项研究成果。

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced an upcoming presentation of preclinical data on the ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will present new data from ...

Trial could ‘usher in a new era’ of affordable antibody therapies to protect against dangerous infectious diseases like Mers, ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss., ...

As artificial intelligence continues to evolve, especially here in the Bay Area, one lab is working to use AI technology to ...

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...